News

TAG24 on MSN8m
Study: Wegovy cuts heart disease risk even before people shed weight
The weight-loss drug Wegovy slashes the risk of heart disease even before people shed many pounds, data suggests.The drug, which contains the active ingredient semaglutide, works by reducing food ...
Ignore The Noise - Novo Nordisk Is A Clear Buy
Novo Nordisk's current product portfolio is well-protected by patents until at least 2030. Click here to see why NVO stock is ...
Novo Nordisk Strikes $2.2 Billion Deal With Septerna to Develop New Obesity Treatments
COPENHAGEN (Reuters) -Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral ...
Devdiscourse21h
Novo Nordisk and Septerna Team Up for Groundbreaking Obesity Treatments
Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...
Novo Nordisk Q1 2025: One Of The Best Deals You Can Get Right Now
Novo Nordisk's Q1 2025 results show a 19% sales increase, 20% operating income growth, and 14% net profit rise. Read why NVO ...
Novo Nordisk hopes to see US Wegovy sales recover soon
Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound ...
Novo Nordisk's latest bet on obesity pills: $2.2 billion for biotech Sapterna
Novo Nordisk (NVO) announced a new $2.2 billion deal with San Francisco-based biotech Sapterna (SEPN) for obesity pills.